PURPOSE: GI stromal tumors (GISTs) are commonly associated with somatic mutations in KIT and PDGFRA. However, a subset arises from mutations in NF1, most commonly associated with neurofibromatosis type 1. We define the anatomic distribution of NF1 alterations in GIST. METHODS: We describe the demographic/clinicopathologic features of 177 patients from two institutions whose GISTs underwent next-generation sequencing of ≥315 cancer-related genes. RESULTS: We initially identified six (9.7%) of 62 GISTs with NF1 genomic alterations from the first cohort. Of these six patients, five (83.3%) had unifocal tumors at the duodenal-jejunal flexure (DJF). Two additional patients with DJF GISTs had non-NF1 (KIT and BRAF) genomic alterations. After excluding one DJF GIST with an NF1 single nucleotide polymorphism, four (57.1%) of seven sequenced DJF tumors demonstrated deleterious NF1 alterations, whereas only one (1.8%) of 55 sequenced non-DJF GISTs had a deleterious NF1 somatic mutation (P < .001). One patient with DJF GIST had a germline NF1 variant that was associated with incomplete penetrance of clinical neurofibromatosis type 1 features along with a somatic NF1 mutation. Of the five DJF GISTs with any NF1 alteration, three (60%) had KIT mutations, and three (60%) had Notch pathway mutations (NOTCH2, MAML2, CDC73). We validated these findings in a second cohort of 115 GISTs, where two (40%) of five unifocal NF1-mutated GISTs arose at the DJF, and one of these also had a Notch pathway mutation (EP300). CONCLUSION: Broad genomic profiling of adult GISTs has revealed that NF1 alterations are enriched in DJF GISTs. These tumors also may harbor concurrent activating KIT and/or inactivating Notch pathway mutations. In some cases, germline NF1 genetic testing may be appropriate for patients with DJF GISTs.
PURPOSE: GI stromal tumors (GISTs) are commonly associated with somatic mutations in KIT and PDGFRA. However, a subset arises from mutations in NF1, most commonly associated with neurofibromatosis type 1. We define the anatomic distribution of NF1 alterations in GIST. METHODS: We describe the demographic/clinicopathologic features of 177 patients from two institutions whose GISTs underwent next-generation sequencing of ≥315 cancer-related genes. RESULTS: We initially identified six (9.7%) of 62 GISTs with NF1 genomic alterations from the first cohort. Of these six patients, five (83.3%) had unifocal tumors at the duodenal-jejunal flexure (DJF). Two additional patients with DJF GISTs had non-NF1 (KIT and BRAF) genomic alterations. After excluding one DJF GIST with an NF1 single nucleotide polymorphism, four (57.1%) of seven sequenced DJF tumors demonstrated deleterious NF1 alterations, whereas only one (1.8%) of 55 sequenced non-DJF GISTs had a deleterious NF1 somatic mutation (P < .001). One patient with DJF GIST had a germline NF1 variant that was associated with incomplete penetrance of clinical neurofibromatosis type 1 features along with a somatic NF1 mutation. Of the five DJF GISTs with any NF1 alteration, three (60%) had KIT mutations, and three (60%) had Notch pathway mutations (NOTCH2, MAML2, CDC73). We validated these findings in a second cohort of 115 GISTs, where two (40%) of five unifocal NF1-mutated GISTs arose at the DJF, and one of these also had a Notch pathway mutation (EP300). CONCLUSION: Broad genomic profiling of adult GISTs has revealed that NF1 alterations are enriched in DJF GISTs. These tumors also may harbor concurrent activating KIT and/or inactivating Notch pathway mutations. In some cases, germline NF1 genetic testing may be appropriate for patients with DJF GISTs.
Authors: Grace L Ma; James D Murphy; Maria E Martinez; Jason K Sicklick Journal: Cancer Epidemiol Biomarkers Prev Date: 2014-10-02 Impact factor: 4.254
Authors: Yiwen Li; Prakash K Rao; Rong Wen; Ying Song; David Muir; Peggy Wallace; Samantha J van Horne; Gihan I Tennekoon; Tom Kadesch Journal: Oncogene Date: 2004-02-05 Impact factor: 9.867
Authors: Gerardo A Vitiello; Timothy G Bowler; Mengyuan Liu; Benjamin D Medina; Jennifer Q Zhang; Nesteene J Param; Jennifer K Loo; Rachel L Goldfeder; Frederic Chibon; Ferdinand Rossi; Shan Zeng; Ronald P DeMatteo Journal: J Clin Invest Date: 2019-02-14 Impact factor: 14.808
Authors: Eleftherios A Makris; Ashwyn K Sharma; Erik N Bergstrom; Xiaojun Xu; Jorge de la Torre; Sudeep Banerjee; Vi Nguyen; Mojgan Hosseini; Adam Burgoyne; Olivier Harismendy; Ludmil B Alexandrov; Jason K Sicklick Journal: JCO Precis Oncol Date: 2021-03-19
Authors: Sudeep Banerjee; Christopher L Corless; Markku M Miettinen; Sangkyu Noh; Rowan Ustoy; Jessica L Davis; Chih-Min Tang; Mayra Yebra; Adam M Burgoyne; Jason K Sicklick Journal: J Transl Med Date: 2019-07-30 Impact factor: 5.531
Authors: Magdalena Koczkowska; Tom Callens; Alicia Gomes; Angela Sharp; Yunjia Chen; Alesha D Hicks; Arthur S Aylsworth; Amedeo A Azizi; Donald G Basel; Gary Bellus; Lynne M Bird; Maria A Blazo; Leah W Burke; Ashley Cannon; Felicity Collins; Colette DeFilippo; Ellen Denayer; Maria C Digilio; Shelley K Dills; Laura Dosa; Robert S Greenwood; Cristin Griffis; Punita Gupta; Rachel K Hachen; Concepción Hernández-Chico; Sandra Janssens; Kristi J Jones; Justin T Jordan; Peter Kannu; Bruce R Korf; Andrea M Lewis; Robert H Listernick; Fortunato Lonardo; Maurice J Mahoney; Mayra Martinez Ojeda; Marie T McDonald; Carey McDougall; Nancy Mendelsohn; David T Miller; Mari Mori; Rianne Oostenbrink; Sebastién Perreault; Mary Ella Pierpont; Carmelo Piscopo; Dinel A Pond; Linda M Randolph; Katherine A Rauen; Surya Rednam; S Lane Rutledge; Veronica Saletti; G Bradley Schaefer; Elizabeth K Schorry; Daryl A Scott; Andrea Shugar; Elizabeth Siqveland; Lois J Starr; Ashraf Syed; Pamela L Trapane; Nicole J Ullrich; Emily G Wakefield; Laurence E Walsh; Michael F Wangler; Elaine Zackai; Kathleen B M Claes; Katharina Wimmer; Rick van Minkelen; Alessandro De Luca; Yolanda Martin; Eric Legius; Ludwine M Messiaen Journal: Genet Med Date: 2018-09-07 Impact factor: 8.822
Authors: Ashwyn K Sharma; Jorge de la Torre; Nikki S IJzerman; Thomas L Sutton; Beiqun Zhao; Tahsin M Khan; Sudeep Banerjee; Christina Cui; Vi Nguyen; Maha Alkhuziem; Petur Snaebjornsson; Hester van Boven; Annemarie Bruining; Chih-Min Tang; Hyunho Yoon; Alexa De la Fuente; Shumei Kato; Hitendra Patel; Michael C Heinrich; Christopher L Corless; Santiago Horgan; Adam M Burgoyne; Paul Fanta; Jill P Mesirov; Andrew M Blakely; Jeremy L Davis; Skye C Mayo; Winan J van Houdt; Neeltje Steeghs; Jason K Sicklick Journal: Clin Cancer Res Date: 2021-10-01 Impact factor: 12.531